Abstract

Background: A quantitative molecular breast imaging (MBI) utility patent (FMTVDM*), previously validated at experienced MBI centers was independently tested for clinical application at a private practice Reno, Nevada cardiologists office. Of the women studied, four were known to have dense breasts.

Methods: Using FMTVDM, a private practice cardiologist and nuclear technologist investigated four women with dense breasts, including 13-specific regions of interest (ROI). The results were compared with the mammographic and tissue findings from the medical record.

Results: Four women with dense breasts were told they had breast cancer by mammography. The medical record and measured FMTVDM found one woman had ductal carcinoma in-situ (DCIS) and another had breast cancer. Two of the four had no evidence of DCIS or cancer.

Conclusions: FMTVDM quantitative MBI measurements correctly identified the cancer and DCIS patients, while additionally correctly identifying one of the two remaining women as having inflammatory breast changes and the final woman having no evidence of inflammation or cancer. While mammography misdiagnosed 50% of the women with dense breasts, FMTVDM correctly identified the breast tissue by measuring the metabolic and regional blood flow in the breasts – correctly identifying the dense tissue as the expected normal fibro glandular tissue present in 50% of all women.

Keywords: FMTVDM; Breast Cancer; Dense Breasts; Nancy Cappello

References

1. Drukteinis JS, Mooney BP, Flowers CI., et al. “Beyond Mammography: New Frontiers in Breast Cancer Screening”. The American Journal of Medicine 126.6 (2013): 472-479.
2. Miller AB, Wall C, Baines CJ. “Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomized screening trial”. British Medical Journal 348 (2014): 366. 
3. The Fleming Method for Tissue and Vascular Differentiation and Metabolism (FMTVDM) using same state single or sequential quantification comparisons (2017). 
4. Fleming RM and Fleming MR. “The Importance of Thinking about and Quantifying Disease like Cancer and Heart Disease on a “Health-Spectrum” Continuum”. J Compr Cancer Rep. 3.1 (2019):1-3. 
5. Fleming RM and Dooley WC. “Breast enhanced scintigraphy testing distinguishes between normal, inflammatory breast changes, and breast cancer: a prospective analysis and comparison with mammography”. Integral Calculator Ther 1.3 (2002): 238-245. 
6. Nancy Cappello. “Breast Cancer Activist Is Dead at 66. By Denise Grady”. New York Times (2018).
7. New federal law requires mammography providers to send breast density notifications. Radiology Business (2019). 

Citation

Citation: Richard M Fleming, Matthew R Fleming, William C Dooley and Tapan K Chaudhuri. “A Possible Solution for Women with Dense Breasts Using FMTVDM to Measure Changes in Breast Tissue". Acta Scientific Medical Sciences 4.2 (2020): 111-114.

Copyright

Copyright: © 2020 Richard M Fleming, Matthew R Fleming, William C Dooley and Tapan K Chaudhuri. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.